chrislal Thursday, 10/03/19 11:11:52 PM Re: DojiMan post# 9140 Post # of 9325 I agree with you, it is not listed at OTC. But there were 150 million and after the RS, it is 6 million. Here is the copy/paste from my brokerage page showing the count. nspyr Therapeutics Inc OTC Pink - Current Information:NSPXDUnited States Search Name or Symbol Enter Name or Symbol Search As of 2019-10-03 at 11:00:34 PM ET RefreshPrintHelp Documentation Collapse Quote Bar LAST PRICE 0.03 TODAY'S CHANGE (%) 0.00 (0.00%) As of 2019-10-03 COMPANY INFORMATION Inspyr Therapeutics, Inc., formerly GenSpera, Inc., is an integrated biopharmaceutical company. The Company is focused on the development of therapies to treat cancer, inflammation, and other diseases. It operates a technology platform based on adenosine chemistry and biology. Its product pipeline includes Mipsagargin; A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B Dual Antagonist. The Company is developing Mipsagargin for different tumor types, including Hepatocellular carcinoma (liver cancer), Glioblastoma (brain cancer) and Prostate cancer. The other combinations of Mipsagargin include PD1/PDL1 combination and Xenograft models. The A2A antagonist; A2B antagonist; A2A agonist, and A2A/A2B dual antagonist are its adenosine receptor programs. Contact Information Headquarters2511 N Loop 1604 W Ste 204SAN ANTONIO, TX, United States 78258-4635 Phone210-479-8112 Fax210-479-8113 Executives Interim Chief Executive Officer, DirectorMichael Cain DirectorJohn Montgomery DirectorClaire Thom Independent DirectorScott Ogilvie RATINGS Please note that US and Canadian reports and ratings may both appear in this module for interlisted securities. The green highlighted bar represents the First Call Consensus rating. No data available At 2019-10-03 11:00 PM ET REPORTS Documents not available0 New Today FUNDAMENTALS Fundamentals Table Market Cap $180.0K Revenue (TTM) $0.00 Shares Outstanding 6.0M Inspyr Therapeutics Inc does not pay a dividend.